The FDA Paused This Biotech's Gene Therapy Study — And Shares Tumbled [Investor's Business Daily]
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Investors Business Daily
Related news 11/05/2019 Mylan stock slipped Tuesday after the pharmaceutical company reported adjusted earnings of $1.17 per share, beating estimates. But sales of... This Big Biotech Just Crushed Earnings Views, Unveiled $1 Billion Buyback Match To Report Plus Pharma, Biotech Earnings Due: Investing Action Plan What Does A Double Bottom Base Look Like? This Top Biotech Stock Formed A Great One Novartis Dips As The World's Most Costly Drug Faces Safety Concerns Merck Stock Is On An Upswing In 2019 — Should You Buy This Pharma Stock? Will This Biotech's Solid Quarter Be Enough To Help It Break Out? Amgen Cuts The Price Of A Key Drug — Prodding A Rival Biotech To Slide Is Biogen Stock A Buy After Rocketing On A New Analysis In Alzheimer's? Regenxbio stock toppled Wednesday after the Food and Drug Administration put one of the biotech company's gene therapy candidates on hold. On the stock market today , shares of Regenxbio ( RGNX ) slumped 3.9
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- REGENXBIO Inc. (NASDAQ: RGNX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $35.00 price target on the stock.MarketBeat
- REGENXBIO Inc. (NASDAQ: RGNX) had its price target lowered by analysts at HC Wainwright from $40.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
- REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.MarketBeat
- REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA [Yahoo! Finance]Yahoo! Finance
- REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATAPR Newswire
RGNX
Earnings
- 11/6/24 - Miss
RGNX
Sec Filings
- 12/9/24 - Form 424B5
- 12/9/24 - Form 8-K
- 11/14/24 - Form SC
- RGNX's page on the SEC website